Clinical trial
A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.
NCT01424566 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 29, 2012
- Completion date
- December 28, 2015
- Enrollment
- 406 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cancer, pain